tirzepatide from lilly gets FDA okay for as obesity therapy https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and

Post hoc analysis of the Exenatide-PD trial-factors that predict response

The thyroid contraindication is precautionary rather than based on established human risk

Semaglutide's safety profile is one of the most thoroughly characterized of any peptide in clinical development, backed by tens of thousands of patient-years of trial data across the STEP and SUSTAIN programs

This can interfere with work, exercise, and daily life

Semaglutide Burping: Whats Normal vs

Could this back-and-forth signal the FDAs concern regarding the reversal of the Chevron decision and its likelihood of success in defending its initial position in court, or is this the FDA wanting to make sure that patients receiving compounded versions of the drug will not be adversely impacted